The role of a soluble TNF a receptor fusion protein ( etanercept ) in corticosteroid refractory asthma : a double blind , randomised , placebo controlled trial

@inproceedings{Morjaria2008TheRO,
  title={The role of a soluble TNF a receptor fusion protein ( etanercept ) in corticosteroid refractory asthma : a double blind , randomised , placebo controlled trial},
  author={Jaymin Bhagwanji Morjaria and Anoop J Chauhan and Kesavan Suresh Babu and Riccardo Polosa and Donna E Davies and Stephen T. Holgate},
  year={2008}
}
Received 28 June 2007 Accepted 19 December 2007 Published Online First 1 February 2008 ABSTRACT Aim: Tumour necrosis factor a (TNFa) is a cytokine recognised as a therapeutic target in chronic inflammatory diseases. Methods: A randomised, double blind, placebo controlled parallel group trial is reported of etanercept (an IgG1-TNF p75 receptor fusion protein), administered once weekly for 12 weeks in 39 patients with severe corticosteroid refractory asthma. Efficacy was measured by change from… CONTINUE READING